Multiple myeloma cells are highly proliferative ... associated with ADC therapy is keratopathy, or toxicity to the eye's corneal epithelium, which may lead patients to discontinue ADC treatments.

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treatment landscape for multiple myeloma. The US Food and Drug ...

Multiple myeloma is a kind of blood cancer that starts in plasma cells. Inside most of your bones is a soft, spongy tissue called bone marrow. Here, your body makes hundreds of thousands of red ...

A multiple myeloma diagnosis is a life event that can be overwhelming. Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... drug has been associated with side effects, particularly eye toxicity, that some analysts believe could limit its ...

A stem cell transplant can be a good treatment for multiple myeloma. A successful transplant gives someone with multiple myeloma new, healthy bone marrow. It replaces the bone marrow harmed by myeloma ...

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...